GSK’s ViiV to buy HIV drugs from BMS


Bristol-Myers Squibb (BMS) has agreed to sell its entire portfolio of investigational HIV drugs as the company seeks to exit research in virology.

ViiV Healthcare – a joint venture predominantly owned by GlaxoSmithKline – will pay $350 million (£240 million) up front, performance milestones of up to $518 million for products already in clinical trials and up to $587 million for discovery and pre-clinical programmes. For any successful drugs that are commercialised, ViiV will pay an extra $700–750 million in sales milestones, plus royalties.

Approximately 20 BMS employees are being offered the option of transferring to ViiV along with the projects.


Related Content

GSK commits to HIV research

19 May 2015 Business

news image

Firm will partner with US university and cancels plan to sell its share of ViiV Healthcare joint venture

Bristol-Myers Squibb to buy Cardioxyl for heart drug

3 November 2015 Business

news image

Deal worth up to $2bn gives BMS full rights to Phase II clinical candidate

Most Commented

Ethanol to butanol conversion shows sustainable potential

13 January 2016 Research

news image

Borrowed hydrogen chemistry drives reaction to obtain useful fuel from biomass

Israeli chemists urge government to ban chemical weapons

21 July 2016 News and Analysis

news image

Open letter presses prime minister to ‘remove the curse of chemical weapons from the face of the Earth’